Citius Oncology (CTOR) Enterprise Value (2022 - 2026)

Citius Oncology's Enterprise Value history runs 5 years deep, the most recent figure standing at -$2.6 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 2350466.07% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at -$2.6 million (down 2350466.07% YoY), while the FY2025 annual figure was -$3.9 million, down 3504282.14% from the prior year.
• Enterprise Value was -$2.6 million for Q1 2026 at Citius Oncology, up from -$7.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$112.0 in Q3 2024 to a low of -$7.3 million in Q4 2025.
• Historically, Enterprise Value has averaged -$1.2 million across 5 years, with a median of -$76853.0 in 2023.
• Biggest YoY gain for Enterprise Value was 99.66% in 2025; the steepest drop was 6513695.54% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$289175.0 in 2022, then soared by 90.83% to -$26523.0 in 2023, then surged by 99.58% to -$112.0 in 2024, then sank by 6513695.54% to -$7.3 million in 2025, then surged by 63.91% to -$2.6 million in 2026.
• The last three Enterprise Value figures came in at -$2.6 million (Q1 2026), -$7.3 million (Q4 2025), and -$3.9 million (Q3 2025), per Business Quant data.